Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...

President Trump's pick to lead the Department of Health and Human Services (HHS), Robert F Kennedy Jr, will be scrutinised at ...

BV100 is a new formulation of rifabutin suitable for intravenous administration that BioVersys claims offers a new mechanism ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

The ranges were 4.5 to nine years for men and 6.5 to 11 years for women, according to the researchers, who have published ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

The UK government has launched a £150 million ($185 million) procurement drive for artificial intelligence solutions that can ...

The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...